Detalhe da pesquisa
1.
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.
Haematologica
; 103(7): 1209-1217, 2018 07.
Artigo
Inglês
| MEDLINE | ID: mdl-29674504
2.
Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease.
Cancer
; 118(2): 434-43, 2012 Jan 15.
Artigo
Inglês
| MEDLINE | ID: mdl-21732338
3.
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis.
Crit Rev Oncol Hematol
; 130: 27-35, 2018 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-30196909
4.
Bortezomib-Induced Muscle Toxicity in Multiple Myeloma.
J Neuropathol Exp Neurol
; 76(7): 620-630, 2017 Jul 01.
Artigo
Inglês
| MEDLINE | ID: mdl-28863457
5.
Bortezomib, Thalidomide and Lenalidomide: Have They Really Changed the Outcome of Multiple Myeloma?
Anticancer Res
; 36(3): 1059-65, 2016 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-26976998
6.
Cytomegalovirus infection in patients undergoing autologous peripheral blood stem cell transplantation.
Int J Infect Dis
; 6(1): 83-4, 2002 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-12118431
7.
Prevalence of hepatitis C virus infection in IgM-type monoclonal gammopathy of uncertain significance and Waldenström macroglobulinemia.
Am J Hematol
; 77(4): 421, 2004 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-15551289